vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and STRATTEC SECURITY CORP (STRT). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($156.4M vs $137.5M, roughly 1.1× STRATTEC SECURITY CORP). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs 5.9%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs 7.7%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

STRATTEC Security Corp designs, manufactures and markets mechanical and electronic security access products, including automotive locks, keys, passive entry systems, and trunk release mechanisms. It primarily serves global automotive original equipment manufacturers, heavy-duty vehicle makers, and the automotive aftermarket across North America, Europe and Asia Pacific.

BCRX vs STRT — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.1× larger
BCRX
$156.4M
$137.5M
STRT
Growing faster (revenue YoY)
BCRX
BCRX
+1.6% gap
BCRX
7.5%
5.9%
STRT
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
7.7%
STRT

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
BCRX
BCRX
STRT
STRT
Revenue
$156.4M
$137.5M
Net Profit
$4.9M
Gross Margin
16.5%
Operating Margin
13.6%
3.5%
Net Margin
3.6%
Revenue YoY
7.5%
5.9%
Net Profit YoY
275.1%
EPS (diluted)
$0.00
$1.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
STRT
STRT
Q1 26
$156.4M
Q4 25
$406.6M
$137.5M
Q3 25
$159.4M
$152.4M
Q2 25
$163.4M
$152.0M
Q1 25
$145.5M
$144.1M
Q4 24
$131.5M
$129.9M
Q3 24
$117.1M
$139.1M
Q2 24
$109.3M
Net Profit
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
$245.8M
$4.9M
Q3 25
$12.9M
$8.5M
Q2 25
$5.1M
$8.3M
Q1 25
$32.0K
$5.4M
Q4 24
$-26.8M
$1.3M
Q3 24
$-14.0M
$3.7M
Q2 24
$-12.7M
Gross Margin
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
97.7%
16.5%
Q3 25
98.6%
17.3%
Q2 25
98.3%
16.7%
Q1 25
96.9%
16.0%
Q4 24
95.4%
13.2%
Q3 24
97.3%
13.6%
Q2 24
98.4%
Operating Margin
BCRX
BCRX
STRT
STRT
Q1 26
13.6%
Q4 25
64.0%
3.5%
Q3 25
18.6%
6.9%
Q2 25
18.2%
5.6%
Q1 25
14.6%
4.9%
Q4 24
-3.4%
1.6%
Q3 24
6.6%
3.6%
Q2 24
8.0%
Net Margin
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
60.5%
3.6%
Q3 25
8.1%
5.6%
Q2 25
3.1%
5.4%
Q1 25
0.0%
3.7%
Q4 24
-20.4%
1.0%
Q3 24
-12.0%
2.7%
Q2 24
-11.6%
EPS (diluted)
BCRX
BCRX
STRT
STRT
Q1 26
$0.00
Q4 25
$1.13
$1.20
Q3 25
$0.06
$2.07
Q2 25
$0.02
$2.02
Q1 25
$0.00
$1.32
Q4 24
$-0.13
$0.32
Q3 24
$-0.07
$0.92
Q2 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
STRT
STRT
Cash + ST InvestmentsLiquidity on hand
$259.0M
$99.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$236.8M
Total Assets
$465.1M
$392.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
STRT
STRT
Q1 26
$259.0M
Q4 25
$274.7M
$99.0M
Q3 25
$212.9M
$90.5M
Q2 25
$260.0M
$84.6M
Q1 25
$295.1M
$62.1M
Q4 24
$320.9M
$42.6M
Q3 24
$96.8M
$34.4M
Q2 24
$78.4M
Stockholders' Equity
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
$-119.2M
$236.8M
Q3 25
$-387.9M
$230.5M
Q2 25
$-421.6M
$221.6M
Q1 25
$-451.9M
$210.7M
Q4 24
$-475.9M
$204.5M
Q3 24
$-468.6M
$203.0M
Q2 24
$-475.6M
Total Assets
BCRX
BCRX
STRT
STRT
Q1 26
$465.1M
Q4 25
$514.2M
$392.2M
Q3 25
$446.4M
$390.1M
Q2 25
$457.2M
$391.5M
Q1 25
$480.0M
$387.4M
Q4 24
$490.4M
$355.9M
Q3 24
$491.3M
$366.9M
Q2 24
$472.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
STRT
STRT
Operating Cash FlowLast quarter
$13.9M
Free Cash FlowOCF − Capex
$11.3M
FCF MarginFCF / Revenue
8.2%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
2.81×
TTM Free Cash FlowTrailing 4 quarters
$67.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
$292.0M
$13.9M
Q3 25
$41.6M
$11.3M
Q2 25
$41.3M
$30.2M
Q1 25
$-27.5M
$20.7M
Q4 24
$-5.2M
$9.4M
Q3 24
$8.2M
$11.3M
Q2 24
$-1.4M
Free Cash Flow
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
$291.2M
$11.3M
Q3 25
$40.3M
$9.8M
Q2 25
$41.1M
$27.2M
Q1 25
$-27.7M
$19.6M
Q4 24
$-5.9M
$8.5M
Q3 24
$8.2M
$9.3M
Q2 24
$-1.5M
FCF Margin
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
71.6%
8.2%
Q3 25
25.3%
6.4%
Q2 25
25.2%
17.9%
Q1 25
-19.0%
13.6%
Q4 24
-4.5%
6.6%
Q3 24
7.0%
6.7%
Q2 24
-1.4%
Capex Intensity
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
0.2%
1.9%
Q3 25
0.8%
1.0%
Q2 25
0.1%
2.0%
Q1 25
0.1%
0.8%
Q4 24
0.5%
0.7%
Q3 24
0.1%
1.5%
Q2 24
0.1%
Cash Conversion
BCRX
BCRX
STRT
STRT
Q1 26
Q4 25
1.19×
2.81×
Q3 25
3.23×
1.33×
Q2 25
8.12×
3.65×
Q1 25
-859.91×
3.84×
Q4 24
7.16×
Q3 24
3.06×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

STRT
STRT

Door Handles And Exterior Trim$35.0M25%
Power Access Solutions$34.5M25%
Keys And Locksets$26.8M19%
Latches$16.3M12%
User Interface Controls$12.5M9%
Aftermarket And Service$9.4M7%
Other Product$3.1M2%
Related Party$1.3M1%

Related Comparisons